In older patients with diabetes, iGlarLixi mitigated insulin-associated weight gain compared with insulin glargine.
In plain wordsIn older patients with diabetes, iGlarLixi reduced insulin-associated weight gain compared with insulin glargine.
- Peptide
- Lixisenatide
- Outcome
- DecreaseInsulin-associated weight gain
- Study
n: not reported in source
- Comparator
- Insulin glargine
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- Dose not stated
Source sentences
Treatment with iGlarLixi mitigated insulin-associated weight gain and lixisenatide-associated gastrointestinal events.
1 context sentence(design, population, supporting numbers)
This post hoc analysis used patient-level data from patients aged ≥65 years from the phase III LixiLan-O and LixiLan-L studies, which compared iGlarLixi with iGlar and lixisenatide (LixiLan-O only).